Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Criteria: * ECOG performance status 0-2 * Platelet count \>= 100,000/mm\^3 * Fertile patients must agree to use effective contraception * No history of inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis) * No invasive malignancy within the past 5 years except nonmelanoma skin cancer or colorectal cancer * No history of endoscopically-confirmed peptic ulcer disease * No history of allergic reactions attributed to compounds of similar chemical or biological composition to the study agents * No history of chronic liver disease or unexplained persistent elevations of serum transaminases * No history of allergic-type reactions, including asthma or urticaria, to aspirin or NSAIDs * No uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness or social situations that would preclude study compliance * At least 6 weeks since prior oral corticosteroids * Creatinine =\< 1.5 times ULN * Creatine phosphokinase =\< 1.5 times ULN * Not pregnant or nursing * At least 6 weeks since prior statins * At increased risk for developing sporadic colorectal neoplasia, as defined by 1 of the following: * History of colon cancer (excluding stage IV or Dukes' D tumors) * Must have completed prior adjuvant therapy for colon cancer \>= 12 months ago * History of colorectal adenomas, meeting any of the following criteria: * \>= 1 cm in diameter * \>= 3 in total number * Any component of villous morphology * High-grade dysplasia * At least 5 rectal aberrant cryptic foci (ACF), by magnification chromoendoscopy, meeting both of the following criteria: * At least 5 aggregated crypts in a single grouping (maximum spacing between crypts must be =\< 2 times the average crypt diameter) * Crypt diameter \>= 1.5 times the diameter of surrounding normal crypts * No history of rectal cancer, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer * Negative pregnancy test * At least 6 months since prior and no concurrent regular use\* of nonsteroidal anti-inflammatory drugs\*\* (NSAIDs) or statins * Concurrent aspirin at cardioprotective doses (=\< 162.5 mg/day or 325 mg every other day) allowed * No prior rectal surgery involving mucosal resection * No prior pelvic radiation therapy * No concurrent regular use\* of cyclooxygenase-2 inhibitors * No concurrent anticoagulant drugs (i.e., warfarin, heparin, clopidogrel bisulfate, or extended-release dipyridamole) * No concurrent use of any of the following: * Fibrates (e.g., gemfibrozil or fenofibrate) * Cyclosporine * Erythromycin or macrolide antibiotics * Protease inhibitors * Azole antifungals * Diltiazem * Verapamil * Compounds containing niacin or nicotinic acid * Defined as 7 consecutive days for \> 3 weeks OR \> 21 days total during study participation * Patients may be eligible for study treatment after discontinuing NSAIDs for 12 weeks, at the discretion of their health care provider * No other concurrent investigational agents * No planned (or likely to require) clinically indicated colonoscopy or flexible sigmoidoscopy during study treatment * Bilirubin =\< 1.5 times ULN * Hemoglobin \>= lower limit of normal * AST =\< 1.5 times upper limit of normal (ULN) * Alkaline phosphatase =\< 1.5 times ULN